Description
CJC-1295 + Ipamorelin Blend | Dual GH-Axis Research Combination
This research blend combines two mechanistically complementary growth hormone-axis peptides: CJC-1295 (No DAC) — a GHRH analogue — with Ipamorelin — a selective GHS-R1a agonist. The combination exploits two distinct GH secretory pathways: somatotroph GHRH receptor stimulation (CJC-1295) and ghrelin receptor agonism (Ipamorelin). Preclinical data consistently demonstrate additive-to-synergistic GH release compared to either peptide alone. Supplied as a co-lyophilised blend at 10mg CJC-1295 + 5mg Ipamorelin.
Mechanism of Action
- CJC-1295 (GHRH analogue) — binds GHRH receptor on pituitary somatotrophs; stimulates GH synthesis and release via cAMP/PKA pathway
- Ipamorelin (GHS-R1a agonist) — selectively activates ghrelin receptor on pituitary and hypothalamus; potentiates GH release via distinct PKC pathway
- Synergistic GH pulse — dual-pathway stimulation produces GH release exceeding either peptide alone in combinatorial research models
- Selective secretagogue profile — Ipamorelin’s selectivity avoids cortisol/prolactin secretion seen with GHRP-2/GHRP-6
Research Areas
The CJC-1295/Ipamorelin blend is studied in GH secretagogue pharmacology, IGF-1 axis biology, body composition research, and age-related GH decline models. Compare with individual compounds CJC-1295 and Ipamorelin for dose-response and pathway dissection studies.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. H. Wallace –
The CJC-1295 + Ipamorelin blend is ideal for our combinatorial GH axis research. Both peptides verified at stated concentrations by our LC-MS. The blend simplifies our protocol considerably without sacrificing accuracy. COA was detailed.
M. Eriksson –
Excellent blend for GH secretagogue research. Independent purity check confirmed >98% for both peptides. Cold-pack delivery was intact on arrival. Will be our standard source going forward.
S. Obi –
Good product. CJC-1295/Ipamorelin blend reconstituted easily and showed expected receptor activity in our assay. The 10mg/5mg ratio matches label claim per our verification. Fast processing and shipping.